WILMINGTON, N.C., March 31 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced it has appointed Mike Wilkinson, Ph.D., as executive vice president of global clinical development. In this role, he will provide strategic leadership to the company's Phase II-IV operations in North America; Latin America; Europe, Middle East and Africa; and Asia Pacific.
"Mike Wilkinson brings an exceptional resume with strong leadership across a variety of roles and is uniquely qualified to direct our Phase II-IV global clinical development operations," said William Sharbaugh, chief operating officer. "With more than 25 years of project management experience, he is extremely skilled at building and leading successful project teams and will play a key role in helping us strategically expand our global operations."
Dr. Wilkinson most recently served as global head of internal medicine and vice president of project management for another contract research organization. His responsibilities included global operational and financial oversight and accountability for all internal medicine clinical trials. His industry experience also includes a tenure as clinical development project management practice leader at a pharmaceutical consulting organization.
Prior to joining the biopharmaceutical industry eight years ago, Dr. Wilkinson spent 27 years in the U.S. military where he began his career as a Navy SEAL. His many roles included aviation physiologist, White House liaison officer with Marine One Executive Transport, director of operations for the Joint Special Operations Medical Training Center and project director for the V-22 Osprey military aircraft.
He earned a doctorate in physiological optics from Indiana University, a master's degree from Penn State University and a bachelor's from Ohio University.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations
and assumptions contained in this news release, including expectations and
assumptions about the above-named employee's performance, are
forward-looking statements that involve a number of risks and
uncertainties. Although PPD attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might
differ from the assumptions on which such statements are based. In
addition, other important factors which could cause results to differ
materially include the following: the ability to attract and retain key
personnel; competition within the outsourcing industry; rapid technological
advances that make our products and services less competitive; continued
success in sales growth; loss of large contracts; increased cancellation
rates; economic conditions and outsourcing trends in the pharmaceutical,
biotechnology, medical device, academic and government industry segments;
risks associated with and dependence on collaborative relationships; risks
associated with the development and commercialization of drugs, including
earnings dilution and obtaining regulatory approval; risks associated with
acquisitions and investments, such as impairments; risks that we may not
continue our dividend policy; and the other risk factors set forth from
time to time in the SEC filings for PPD, copies of which are available free
of charge upon request from the PPD investor relations department.
Sue Ann Pentecost
+919 456 5890
+910 558 7585
|SOURCE PPD, Inc.|
Copyright©2008 PR Newswire.
All rights reserved